| Code | CSB-RA007690MB5HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is a research-grade biosimilar to JS-019, developed for research targeting ENTPD1 (ectonucleoside triphosphate diphosphohydrolase-1), also known as CD39. ENTPD1 is an ectoenzyme that catalyzes the hydrolysis of extracellular ATP and ADP to AMP, playing a critical role in purinergic signaling and immune regulation. By converting pro-inflammatory ATP to adenosine precursors, ENTPD1 modulates immune responses and contributes to immunosuppressive microenvironments. This protein is expressed on various cell types including regulatory T cells, endothelial cells, and tumor-infiltrating lymphocytes, and has been implicated in cancer immune evasion, inflammatory diseases, and transplant tolerance.
JS-019 represents an investigational therapeutic antibody designed to block ENTPD1 activity, potentially enhancing anti-tumor immunity by preventing the generation of immunosuppressive adenosine in the tumor microenvironment. This biosimilar provides researchers with a valuable tool for studying ENTPD1-mediated immune regulation, exploring combination immunotherapy strategies, and investigating purinergic signaling pathways in various disease models.
There are currently no reviews for this product.